Heart failure & cardiomyopathies
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in heart failure: the DECISION trial
Primary result · CV death or worsening HF events after withdrawalResult — go to the resultRelative risk 7.37 95% CI 1.56–34.88Authors' conclusion
Discontinuation of digoxin after long-term treatment is associated with clinical deterioration in patients with HF and a reduced or mildly reduced ejection fraction.
Study context
- Population
- Patients with heart failure (HF) and reduced or mildly reduced EF on guideline-recommended therapy, after median 36.5 months of randomised treatmentof 1001 randomised
- Participants
- 587 patients
- Comparison
- Blinded withdrawal of low-dose digoxin vs placebo
- Primary endpoint
- CV death or worsening HF events after blinded withdrawal
- Follow-up
- 6 weeks
Methodological detailsprespecified analysis, blinded withdrawal, All events were adjudicated
- Prespecified analysis
- Blinded withdrawal
- All events were adjudicated
Primary result
CV death or worsening HF events after withdrawal
Relative risk
7.37
95% CI 1.56–34.88
P = 0.012
Events by treatment group
Digoxinvs Placebo
RR 7.37 (95% CI 1.56–34.88); P = 0.012
As reported in the abstract
Further findings
Events per 100 patient-years
| Outcome | Digoxin | Placebo | Rate ratio (95% CI) | |
|---|---|---|---|---|
| CV death or worsening HF events, pre-withdrawal phase · 100 days | 5.7 | 6.5 | 0.88 (0.24–3.10) | |
| 0.20.5125Rate ratio (log scale) |
Heart rate, SBP, NT-proBNP after digoxin withdrawal
- Increase in heart rate
- P = 0.003
- Reduction in SBP
- P = 0.014
- Rise in NT-proBNP
- P = 0.002
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in heart failure: the DECISION trial. Eur Heart J. Published 10 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →